Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(14):1061; doi:10.1093/jnci/96.14.1061
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Randal, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Randal, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

FDA Panel Scrutinizes Safety of Anti-Anemia Drugs

Judith Randal

The first 10% of the full text of this article appears below.

Commercials on American television that feature cancer patients made anemic—and therefore miserably tired—by chemotherapy and whose energy is restored by the drug Procrit are hard to escape. Given by injection, this drug is a genetically engineered version of erythropoietin, the human hormone—often referred to as EPO or epoetin—that corrects anemia by stimulating the production of red blood cells that ferry oxygen to the body's tissues.

Procrit is made by Amgen and marketed by Johnson & Johnson subsidiary Ortho Biotech Products. It reduces . . . [Full Text of this Article]

Safety Concerns

Possibility of Progression

Advertisements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
P. Gascon
Safety Update on Erythropoiesis-Stimulating Agents: Trials Within and Outside the Accepted Indications
Oncologist, May 1, 2008; 13(suppl_3): 4 - 10.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Stasi, S. Amadori, T. J. Littlewood, E. Terzoli, A. C. Newland, and D. Provan
Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns
Oncologist, August 1, 2005; 10(7): 539 - 554.
[Abstract] [Full Text] [PDF]